首页> 外文期刊>ACS applied materials & interfaces >Multi-targeting Peptide-Functionalized Nanoparticles Recognized Vasculogenic Mimicry, Tumor Neovasculature, and Glioma Cells for Enhanced Anti-glioma Therapy
【24h】

Multi-targeting Peptide-Functionalized Nanoparticles Recognized Vasculogenic Mimicry, Tumor Neovasculature, and Glioma Cells for Enhanced Anti-glioma Therapy

机译:多目标肽功能化的纳米粒子公认的血管生成模仿,肿瘤新脉管系统和胶质瘤细胞,以增强抗胶质瘤治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

Chemotherapy failure of glioma, the most aggressive and devastating cancer, might be ascribed to the physiologic barriers of the tumor mainly including heterogeneous tumor perfusion and vascular permeability, which result in a limited penetration of chemotherapeutics. Besides, the vasculogenic mimicry (VM) channels, which are highly resistant to anti-angiogenic therapy and serve as a complement of angiogenesis, were abound in glioma and always associated with tumor recurrence. In order to enhance the therapy effect of anti-glioma, we developed a PEG-PLA-based nanodrug delivery system (nanoparticles, NP) in this study and modified its surface with CK peptide, which was composed of a human sonic hedgehog (SETH) targeting peptide (CVNHPAFAC) and a KDR targeting peptide (K237) through a GYG linker, for facilitating efficient VM channels, tumor neovasculature, and glioma cells multi-targeting delivery of paclitaxel. In vitro cellular assay showed that CK-NP-PTX not only exhibited the strongest antiproliferation effect on U87MG cells and HUVEC cells but also resulted in the most efficient destruction of VM channels when compared with CVNHPAFAC-NP, K237-NP, and the unmodified ones. Besides, CK-NP accumulated more selectively at the glioma site as demonstrated by in vivo and ex vivo imaging. As expected, the glioma-bearing mice treated with CK-NP-PTX achieved the longest median survival time compared to those treated with CVNHPAFAC-NP-PTX and K237-NP-PTX. These findings indicated that the multi-targeting therapy mediated by CK peptide might provide a promising way for glioblastoma therapy.
机译:胶质瘤是最具侵略性和破坏性的癌症,其化疗失败可能归因于肿瘤的生理障碍,主要包括异质性肿瘤灌注和血管通透性,导致化疗药物的渗透受限。此外,对抗血管生成疗法具有高度抗性并作为血管生成的补充的血管生成模拟通道(VM)在神经胶质瘤中比比皆是,并且总是与肿瘤复发相关。为了增强抗神经胶质瘤的治疗效果,我们在本研究中开发了基于PEG-PLA的纳米药物递送系统(纳米颗粒,NP),并用由人声刺猬(SETH)组成的CK肽修饰了其表面。靶向肽(CVNHPAFAC)和KDR靶向肽(K237)通过GYG接头,以促进有效的VM通道,肿瘤新脉管系统和神经胶质瘤细胞对紫杉醇的多靶向递送。体外细胞试验表明,与CVNHPAFAC-NP,K237-NP和未修饰的相比,CK-NP-PTX不仅对U87MG细胞和HUVEC细胞表现出最强的抗增殖作用,而且还导致VM通道最有效的破坏。 。另外,如体内和离体成像所证实的,CK-NP在神经胶质瘤部位更选择性地积累。如所预期的,与用CVNHPAFAC-NP-PTX和K237-NP-PTX治疗的小鼠相比,用CK-NP-PTX治疗的具有神经胶质瘤的小鼠获得了最长的中位存活时间。这些发现表明CK肽介导的多靶点治疗可能为胶质母细胞瘤治疗提供了一种有希望的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号